We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AXSM market cap is 4.53B. The company's latest EPS is USD -4.9366 and P/E is -18.94.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 57.79M | 71.53M | 75M | 87.17M | 104.76M |
| Operating Income | -62.3M | -55.07M | -68.69M | -75.89M | -46.23M |
| Net Income | -62.2M | -98.65M | -68.36M | -79.35M | -64.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 50.04M | 270.6M |
| Operating Income | -67.25M | -99.14M | -124.71M | -176.5M | -182.91M |
| Net Income | -68.35M | -102.9M | -130.4M | -187.13M | -239.24M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 600.86M | 588.24M | 545.73M | 548.23M | 561.46M |
| Total Liabilities | 331.35M | 397.26M | 401.69M | 445.37M | 468.56M |
| Total Equity | 269.51M | 190.98M | 144.04M | 102.85M | 92.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 220.55M | 186.13M | 87.79M | 331.48M | 588.24M |
| Total Liabilities | 41.83M | 72.34M | 72.16M | 221.92M | 397.26M |
| Total Equity | 178.72M | 113.79M | 15.63M | 109.56M | 190.98M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -114.72M | -145.08M | -53.47M | -83.58M | -102.21M |
| Investing | -575k | -582k | -98k | -150k | -240k |
| Financing | 331.02M | 331.01M | -1.19M | 13.19M | 43.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -46.38M | -78.46M | -108.23M | -116.51M | -145.08M |
| Investing | -16k | -46k | -307k | -53.7M | -582k |
| Financing | 252.39M | 42.41M | 11.13M | 284.58M | 331.01M |
| Market Cap | 4.53B |
| Price to Earnings Ratio | -18.94 |
| Price to Sales Ratio | 16.75 |
| Price to Cash Ratio | 11.73 |
| Price to Book Ratio | 23.73 |
| Dividend Yield | - |
| Shares Outstanding | 48.46M |
| Average Volume (1 week) | 551.82k |
| Average Volume (1 Month) | 477.67k |
| 52 Week Change | 29.09% |
| 52 Week High | 105.00 |
| 52 Week Low | 64.11 |
| Spread (Intraday) | 44.9 (37.92%) |
| Company Name | Axsome Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.axsome.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
